Can tirzepatide actually boost fertility? Here's what we know

What did @socalurologyinstitute actually say?

The creator, who identifies as a urologist, made a straightforward claim: tirzepatide (sold as Mounjaro and Zepbound) can increase a woman's chances of getting pregnant, primarily by triggering weight loss that restores hormonal balance. The warning attached to this claim is the part that actually matters. "If you're on a semaglutide and you lose weight, make sure you use birth control," the creator said, directing this at women who assume they're subfertile and have stopped using contraception. The mechanism proposed is indirect: GLP-1 drugs cause weight loss, weight loss corrects hormonal dysregulation, corrected hormones improve fertility. The creator is not claiming tirzepatide is a fertility drug in any pharmacological sense. That distinction matters a lot for how we evaluate this.

Does the science back this up?

The indirect mechanism the creator describes is well-supported, though the direct evidence for tirzepatide specifically is still limited. The core claim, that weight loss improves fertility in women with obesity-related hormonal disruption, is not controversial. What is newer is whether GLP-1 receptor agonists produce this effect at a clinically meaningful rate.

A 2023 review by Joham et al. in The Lancet Diabetes and Endocrinology confirmed that obesity-related hyperinsulinemia and elevated androgen levels significantly impair ovulation in women with polycystic ovary syndrome (PCOS). Weight loss of even 5-10% of body weight has been shown to restore menstrual regularity and ovulation in this population. A 2024 observational study by Taha et al. published in Fertility and Sterility reported cases of unintended pregnancies in women using GLP-1 agonists who had previously considered themselves infertile, consistent with what the creator describes from clinical practice. Tirzepatide's dual GIP and GLP-1 receptor agonism produces greater average weight loss than semaglutide alone in head-to-head comparisons (Jastreboff et al., 2022, NEJM), which could theoretically amplify this fertility-restoration effect, though that specific link has not been studied directly.

What did they get wrong (or right)?

Mostly right on the mechanism, a little sloppy on the framing. Calling tirzepatide a drug that "can make you get pregnant" is technically misleading. It is not acting on reproductive tissue or directly stimulating ovulation. It is causing weight loss, and weight loss, in the right patient, may restore fertility. The drug is not doing the fertility work directly. That framing difference matters because it could lead patients to think tirzepatide has properties it does not have.

The creator also conflates semaglutide and tirzepatide throughout the video, using the brand names interchangeably in a way that may confuse patients. These are different drugs with different receptor profiles. The fertility-adjacent data that exists skews toward semaglutide and weight-loss surgery studies, not tirzepatide specifically.

What they got right: the clinical scenario described, where a couple stops using birth control after years of not conceiving and then unexpectedly becomes pregnant after starting a GLP-1 drug, is documented. The contraception warning is appropriate and genuinely underemphasized in prescribing conversations. This is a useful public health message, even if the mechanism is oversimplified.

What should you actually know?

If you are a woman of reproductive age starting tirzepatide or any GLP-1 drug, your prescriber should be asking about contraception. Current guidance from the American College of Obstetricians and Gynecologists advises against using GLP-1 receptor agonists during pregnancy due to insufficient safety data in humans and adverse findings in animal studies. An unintended pregnancy on tirzepatide is not a benign outcome. You would need to stop the drug, and any weight regain could follow.

There is also a practical interaction worth knowing: GLP-1 drugs slow gastric emptying, which may reduce the absorption of oral contraceptive pills. A 2022 pharmacokinetic study by Flint et al. in Clinical Pharmacokinetics found that semaglutide modestly reduced peak plasma concentrations of oral contraceptives. The clinical significance is unclear, but it is reason to discuss contraceptive method with your doctor when starting these medications.

The patients most likely to see fertility restoration are those with obesity-related PCOS or anovulation, not women with other causes of infertility. This is not a universal effect.